Incyte Corporation (INCY) Stock Price & Analysis

Incyte Corporation (INCY) closed at USD 116.93 on Thursday, October 22, 2026, up 3.08% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 116.93; the Oct 22, 2026 session ranged USD 112.76–117.17 on volume of 2,235,198 shares. Market capitalization is —, with a 52-week range of USD 84.02–132.6 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:21 UTC.

Also available as compact Markdown for AI agents: nexqual.com/INCY.md

Key facts (INCY)

• Last four reported quarters (through Jun 30, 2026): revenue $5.82B, net income $1.61B (27.7% margin) (SEC filings).
• 2 of 80 tracked superinvestors hold INCY (13F, Q2 2026): 0 new, 0 added, 2 reduced, 0 unchanged.
• Total return with dividends: 1Y +30.9% vs S&P 500 +14.9%; 5Y +77.7% vs S&P 500 +80.3%.
• Next earnings: 2026-10-29, EPS estimate USD -3.84, revenue estimate $1.47B.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (INCY)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (INCY)

P/E at fiscal year-ends: Dec 2025 15.4x, Dec 2024 445.8x, Dec 2023 23.7x.

Superinvestors (SEC 13F-HR, Q2 2026) (INCY)

2 of 80 tracked investors hold INCY. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Analysts (INCY)

Rating changes, last 120 days:

Total return (dividends reinvested) (INCY)

INCY revenue by product line (quarter ended Jun 30, 2026)

INCY revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

INCY suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 10, 2026.

Companies that name INCY in their SEC reports

INCY customer concentration

In the period ended Jun 30, 2026, 6 direct customers each accounted for at least 10% (20%, 19%, 12%, 11%, 10%, 7%) of revenue, per the company's 10-Q filed Jul 28, 2026. The company does not name them.

INCY company outlook (results filed Jul 28, 2026)

• “Incyte is raising its full year 2026 total net sales guidance to $5,130 - $5,260 million, reflecting the impact of the agreement with CMS related to the Opzelura line extension, * as well as the continued strong performance of its Hematology and Oncology growth products, including Niktimvo, Monjuvi/Minjuvi and Zynyz.”
• “Incyte is raising its full year 2026 Opzelura net sales guidance to $1,050 - $1,100 million and full year 2026 Hematology and Oncology net sales guidance to $860 - $890 million.”
• “Incyte is also raising its full year 2026 operating expense guidance.”
• “Total GAAP R&D and SG&A operating expense guidance is $4,915 - $4,995 million and total non-GAAP R&D and SG&A operating expense guidance is $4,625 - $4,695 million.”

Quoted word-for-word from the SEC 8-K results press release.

INCY analyst estimates and revisions

Key Statistics (as of October 23, 2026 at 09:21 UTC)

Technical Analysis (INCY)

Nexqual's technical model rates INCY "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 09:21 UTC.

Earnings (INCY)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:21 UTC.

Financials & Fundamentals (INCY)

Source: Nexqual, October 23, 2026 at 09:21 UTC.

Ownership (INCY)

Source: Nexqual, October 23, 2026 at 09:21 UTC.

From Incyte Corporation's Latest SEC 10-K Filing (filed 2026-02-10)

Key Strengths & Strategy (as disclosed to the SEC)

• We submitted a Type II variation Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA") and, in January 2026, we announced that the Committee for Medicinal Products for Human Use ("CHMP") issued a positive opinion for ZYNYZ in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent SCAC.
• In September 2025, the FDA approved the supplemental New Drug Application ("NDA") for OPZELURA for the short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised children two years of age and older whose disease is not well controlled with topical prescription therapies, or when those therapies are not advisable.

Partnerships

• In October 2025, we announced an agreement with Enable Injections, Inc. ("Enable") to develop for use with specific assets in our portfolio, including INCA033989, Enable's enFuse on-body delivery system.
• In May 2020, we amended our agreement with Lilly to enable Lilly to commercialize baricitinib for the treatment of COVID-19.

Legal & Regulatory Risks (Item 1A, quoted)

• We may be unsuccessful in defending or pursuing these lawsuits, claims or other legal proceedings.
• We may be unable to adequately protect or enforce our proprietary information, which may result in its unauthorized use, a loss of revenue under a collaboration agreement or loss of sales to generic versions of our products or otherwise reduce our ability to compete in developing and commercializing products.
• Increasing use of social media and new technology, including artificial intelligence, could give rise to liability, breaches of data security, or reputational damage.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:21 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt